Navigation Links
PRA International Expert to Speak at China Drug Safety Summit
Date:11/16/2010

RALEIGH, N.C., Nov. 16, 2010 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, announces that the head of our Safety and Risk Management (SRM) group will speak at the 3rd annual China Drug Safety and Public Policy Summit being held in Shanghai 18-19 November 2010.

Dr. Sabine Richter, PRA's Vice President of SRM, will deliver the opening day's keynote address, "Challenges of Drug Safety in Global Clinical Trials." Her presentation will address the challenges and opportunities associated with handling safety data from global studies, including those in Asian countries. She will also review how cultural and regulatory factors affect the collection, reporting, and regulatory acceptance of safety data from trials performed outside of the United States and Europe.

Dr. Richter has over 20 years of research experience in the pharmaceutical and CRO industries, as well as in academia. Since joining PRA's SRM team in 2004, she has delivered numerous projects for a variety of clients and led large, long-term safety programs involving as many as 50 countries on five continents.  

PRA's SRM group has more than 110 experts providing safety and risk management services throughout the entire product life cycle. Most SRM staff members are healthcare professionals (nurses, pharmacists, physicians) or life scientists. They offer consultancy as well as routine and specialty pharmacovigilance services. Our drug safety centers are based in Mannheim, Germany; Charlottesville, VA (US); and Sao Paulo, Brazil.

For more information about the conference, please visit www.prainternational.com and click on "Events."



About PRA International

PRA International conducts clinical trials in more than 85 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in Oncology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. In the last five years, PRA has supported over 3000 clinical trials through its 38 global offices.

PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.

To learn more about PRA International, please visit www.PRAinternational.com, email Endpoints@PRAintl.com or call our Global Headquarters at +1 (919) 786-8200.


'/>"/>
SOURCE PRA International
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
2. Yongye Biotechnology International Retains CCG Investor Relations
3. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
4. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
5. Yongye Biotechnology International Announces Second Quarter Results
6. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
7. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
8. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
9. Mindray Medical International Announces Second Quarter 2008 Results
10. Singapore to hold international pow-wow
11. Sangui BioTech International, Inc. Files Remaining Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, ... Pennsylvania Convention Center and will showcase its product’s latest features from June 26 ... presenting a scientific poster on Disrupting Clinical Trials in The Cloud during the ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:5/24/2016)... 2016 Ampronix facilitates superior patient care by providing unparalleled technology to leaders ... is the latest premium product recently added to the range of products distributed by ... ... ... LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
Breaking Biology News(10 mins):